Purchase this database of 20+ companies developing regulatory T cell based therapies
Regulatory T-cells (Tregs) constitute a major component of the immune system, as the Tregs suppress activation, proliferation and cytokine production of CD4+ T cells and CD8+ T cells, and thus, act as a "brake" for the immune response. The major defining feature of the Treg population is the expression of the nuclear transcription factor Forkhead box P3 (FoxP3). Furthermore, Tregs are characterized as expressing both the CD4 T cell co-receptor and CD25, which is a component of the IL-2 receptor.
Because of the inhibitory effect on cytotoxic T cells mediated by regulatory T cells in the tumor microenvironment (TME), inhibition or depletion of Tregs in the TME is of great interest in cancer research.
Figure 1. The figure shows the immunosuppressive mechanisms underlying Treg-mediated immune suppression. The figure is from Kempkes et al.
In autoimmune and inflammatory diseases, ex vivo expanded and modified Tregs are being studied and developed as cellular therapies to regulate the immune system. One such promising approach involves genetically engineering the Tregs to express a chimeric antigen receptor (CAR), which will then direct Tregs to the tissue of interest.
This database contains more than 20 companies working with Treg cell therapies, this being preclinical or clinical development.
Additionally, you can read more about regulatory T cell companies in general as well as a deeper investigation of Treg company GentiBio, and the technology behind them in the blog post released by Stargazing Bio Research in relation to our regulatory T-cell company database here.